Lindsay K Pino
@lindsaykpino.com
#massspectrometry, #proteomics, and #bioinformatics | hiking and dogs | co-founder & CTO @talusbio | opinions my own
Upcoming talks at Human Proteome Organization! Come check out what Talus Bio has been working on over the last year, from mapping the regulome to manipulating it and modeling it, all using mass spectrometry proteomics as a driving force.
November 10, 2025 at 6:25 AM
Upcoming talks at Human Proteome Organization! Come check out what Talus Bio has been working on over the last year, from mapping the regulome to manipulating it and modeling it, all using mass spectrometry proteomics as a driving force.
Update: it did, indeed, snow at HUPO.
November 9, 2025 at 10:23 PM
Update: it did, indeed, snow at HUPO.
There is, admittedly, a cool collection of mass spec parts that @bushlab.bsky.social gathered together
November 4, 2025 at 7:54 PM
There is, admittedly, a cool collection of mass spec parts that @bushlab.bsky.social gathered together
Day 2, amazing analogy by Evan Williams @berkeleychemistry.bsky.social for charge detection
November 4, 2025 at 7:02 PM
Day 2, amazing analogy by Evan Williams @berkeleychemistry.bsky.social for charge detection
I have to say, there's been a very disappointing lack of mass spec gore so far. How can you have a whole lecture about turbo pumps and no "rest in pieces" graveyard pics??
I'll go first. RIP turbo from @maccoss.bsky.social (believe it was a QE-HF).
I'll go first. RIP turbo from @maccoss.bsky.social (believe it was a QE-HF).
November 3, 2025 at 6:25 PM
I have to say, there's been a very disappointing lack of mass spec gore so far. How can you have a whole lecture about turbo pumps and no "rest in pieces" graveyard pics??
I'll go first. RIP turbo from @maccoss.bsky.social (believe it was a QE-HF).
I'll go first. RIP turbo from @maccoss.bsky.social (believe it was a QE-HF).
Kicking us off is @maccoss.bsky.social , melting my mind at 8am with this observation that LC-MS is really a lossless single molecule compression method at its core.
October 16, 2025 at 3:34 PM
Kicking us off is @maccoss.bsky.social , melting my mind at 8am with this observation that LC-MS is really a lossless single molecule compression method at its core.
Wrapping up the skyline.ms virtual workshop on #MassSpectrometry #proteomics with Advanced Proteomics: data independent acquisition today, post-translational modifications tomorrow. @juank1892.bsky.social @arianashannon.bsky.social @miriamabele.bsky.social (anybody else on bsky?) 🖥️🧬🧪
October 16, 2025 at 3:22 PM
Wrapping up the skyline.ms virtual workshop on #MassSpectrometry #proteomics with Advanced Proteomics: data independent acquisition today, post-translational modifications tomorrow. @juank1892.bsky.social @arianashannon.bsky.social @miriamabele.bsky.social (anybody else on bsky?) 🖥️🧬🧪
Skyline Online Session 3 just kicked off. Ariana Shannon of @mayoclinic.org organized a great 2-day introduction to the skyline.ms software for quantitative mass spectrometry proteomics. 💻🧬 #TeamMassSpec #proteomics
October 14, 2025 at 3:14 PM
Skyline Online Session 3 just kicked off. Ariana Shannon of @mayoclinic.org organized a great 2-day introduction to the skyline.ms software for quantitative mass spectrometry proteomics. 💻🧬 #TeamMassSpec #proteomics
This is actually much longer than I expected. But at least it's not in Latin.
October 14, 2025 at 3:11 PM
This is actually much longer than I expected. But at least it's not in Latin.
On my way back to Seattle after my first Forbeck Forum at the beautiful Lake Geneva. Really interesting conference format: <20 people, 45 minutes to "present", maximum TWO slides. Lots of good discussion and I learned a ton -- and probably got myself into even more work/collaborations 😂
October 8, 2025 at 2:06 PM
On my way back to Seattle after my first Forbeck Forum at the beautiful Lake Geneva. Really interesting conference format: <20 people, 45 minutes to "present", maximum TWO slides. Lots of good discussion and I learned a ton -- and probably got myself into even more work/collaborations 😂
My goal to read more for pleasure this year is going well, largely thanks to scifi/fantasy/YA page-turners, but sometimes (okay okay rarely) I read non-fiction too
www.goodreads.com/book/show/41...
www.goodreads.com/book/show/41...
September 23, 2025 at 1:44 AM
My goal to read more for pleasure this year is going well, largely thanks to scifi/fantasy/YA page-turners, but sometimes (okay okay rarely) I read non-fiction too
www.goodreads.com/book/show/41...
www.goodreads.com/book/show/41...
It was wonderful to meet old and new collaborators in person to catch up on ongoing projects and some exciting new work that's getting kicked off with the Tech Access Program
www.talus.bio/news/talus-b...
www.talus.bio/news/talus-b...
August 29, 2025 at 1:56 PM
It was wonderful to meet old and new collaborators in person to catch up on ongoing projects and some exciting new work that's getting kicked off with the Tech Access Program
www.talus.bio/news/talus-b...
www.talus.bio/news/talus-b...
Congrats to @mannlab.bsky.social on election to the National Academy of Sciences! www.nasonline.org/news/2025-na...
And to @kusterlab.bsky.social for successfully exiting OmicsScouts www.prnewswire.com/news-release...
And @hecklab.bsky.social on launching a newco. www.abvion.bio/team
And to @kusterlab.bsky.social for successfully exiting OmicsScouts www.prnewswire.com/news-release...
And @hecklab.bsky.social on launching a newco. www.abvion.bio/team
August 29, 2025 at 1:54 PM
Congrats to @mannlab.bsky.social on election to the National Academy of Sciences! www.nasonline.org/news/2025-na...
And to @kusterlab.bsky.social for successfully exiting OmicsScouts www.prnewswire.com/news-release...
And @hecklab.bsky.social on launching a newco. www.abvion.bio/team
And to @kusterlab.bsky.social for successfully exiting OmicsScouts www.prnewswire.com/news-release...
And @hecklab.bsky.social on launching a newco. www.abvion.bio/team
I had meant to live-post more of my Boston trip but clearly it was a whirlwind 😂
Excellent conversation with amazing company. And of course THE WHEEL made an appearance! @andreagut95.bsky.social @juliar2bs.bsky.social
Excellent conversation with amazing company. And of course THE WHEEL made an appearance! @andreagut95.bsky.social @juliar2bs.bsky.social
August 29, 2025 at 1:50 PM
I had meant to live-post more of my Boston trip but clearly it was a whirlwind 😂
Excellent conversation with amazing company. And of course THE WHEEL made an appearance! @andreagut95.bsky.social @juliar2bs.bsky.social
Excellent conversation with amazing company. And of course THE WHEEL made an appearance! @andreagut95.bsky.social @juliar2bs.bsky.social
We had the kangaroos in the 90s! They rebooted them or something recently, changed the cookies and reformulated the childhood recipe and it doesn't taste the same anymore. Too many emulsifiers or something.
August 4, 2025 at 2:52 PM
We had the kangaroos in the 90s! They rebooted them or something recently, changed the cookies and reformulated the childhood recipe and it doesn't taste the same anymore. Too many emulsifiers or something.
I also made a Lightning McQueen cake but this one was a boxed mix and a molded cake pan
August 3, 2025 at 5:05 PM
I also made a Lightning McQueen cake but this one was a boxed mix and a molded cake pan
I don't get many opportunities to bake lately, but I love it! Homemade white cake cupcakes with cream cheese frosting and cookie crumble
August 2, 2025 at 10:22 PM
I don't get many opportunities to bake lately, but I love it! Homemade white cake cupcakes with cream cheese frosting and cookie crumble
Didn't get enough #TeamMassSpec at the Cascadia Proteomics conference last week? Did our @talusbio.bsky.social presentations pique your curiosity? Say no more because Bruker has you covered. I'm speaking at the "Bringing ASMS 2025 to Seattle" event TODAY!
Registration still open! lnkd.in/gTs62ePq
Registration still open! lnkd.in/gTs62ePq
July 22, 2025 at 8:04 AM
Didn't get enough #TeamMassSpec at the Cascadia Proteomics conference last week? Did our @talusbio.bsky.social presentations pique your curiosity? Say no more because Bruker has you covered. I'm speaking at the "Bringing ASMS 2025 to Seattle" event TODAY!
Registration still open! lnkd.in/gTs62ePq
Registration still open! lnkd.in/gTs62ePq
I can't tell if I'm bad at describing how I'm thinking about drug discovery and development, or maybe we're just really doing it so weirdly that it doesn't fit the normal expectations. Either way, maybe I should just make a pitch deck entirely from meme templates.
July 22, 2025 at 4:07 AM
I can't tell if I'm bad at describing how I'm thinking about drug discovery and development, or maybe we're just really doing it so weirdly that it doesn't fit the normal expectations. Either way, maybe I should just make a pitch deck entirely from meme templates.
I am far out of my depth when it comes to glycans, but we found the nuclear membrane seemed to be more enriched for LacNAc. (Correct me if I'm wrong on this one, @cashwood.proteaglyco.com !) We should for sure add all this detail into a supplement at minimum though.
July 3, 2025 at 1:45 AM
I am far out of my depth when it comes to glycans, but we found the nuclear membrane seemed to be more enriched for LacNAc. (Correct me if I'm wrong on this one, @cashwood.proteaglyco.com !) We should for sure add all this detail into a supplement at minimum though.
Since the approach is unbiased in protein measurement, we can look across complexes in addition to individual proteins. For example, we can capture how menin inhibitors (covalent and not) remodel the MLL1 complex. (Since we use MS, we even have the peptide-level evidence of covalent binding.)
9/?
9/?
July 2, 2025 at 3:55 PM
Since the approach is unbiased in protein measurement, we can look across complexes in addition to individual proteins. For example, we can capture how menin inhibitors (covalent and not) remodel the MLL1 complex. (Since we use MS, we even have the peptide-level evidence of covalent binding.)
9/?
9/?
We also screened 299 drugs (the Enamine CLOUD library) for regulome effects. The majority of these drugs don't explicitly target chromatin-binding proteins, but could have downstream "off-target" effects.
Most drugs do nothing to the regulome, but some proteins are "sensitive" to many drugs.
Most drugs do nothing to the regulome, but some proteins are "sensitive" to many drugs.
July 2, 2025 at 3:48 PM
We also screened 299 drugs (the Enamine CLOUD library) for regulome effects. The majority of these drugs don't explicitly target chromatin-binding proteins, but could have downstream "off-target" effects.
Most drugs do nothing to the regulome, but some proteins are "sensitive" to many drugs.
Most drugs do nothing to the regulome, but some proteins are "sensitive" to many drugs.
Beyond cell lines, there's also cell stimulations we can compare. In THP-1 cells, 2 hr of immune stimulation triggers chromatin recruitment of NFkB, IRFs, BRD4, p300, etc.
Different ligands give different TF and cofactor signatures, unsurprisingly!
7/?
Different ligands give different TF and cofactor signatures, unsurprisingly!
7/?
July 2, 2025 at 3:43 PM
Beyond cell lines, there's also cell stimulations we can compare. In THP-1 cells, 2 hr of immune stimulation triggers chromatin recruitment of NFkB, IRFs, BRD4, p300, etc.
Different ligands give different TF and cofactor signatures, unsurprisingly!
7/?
Different ligands give different TF and cofactor signatures, unsurprisingly!
7/?
The most obvious thing to do is to compare different cell lines. Looking across the soluble/accessible chromatin fractions, the master regulators behave as expected: AR interacting with chromatin in prostate, PAX8 in ovarian, MYCN in neuroblastoma, MYOD1 in rhabdo, TBXT in chordoma, etc.
6/?
6/?
July 2, 2025 at 3:39 PM
The most obvious thing to do is to compare different cell lines. Looking across the soluble/accessible chromatin fractions, the master regulators behave as expected: AR interacting with chromatin in prostate, PAX8 in ovarian, MYCN in neuroblastoma, MYOD1 in rhabdo, TBXT in chordoma, etc.
6/?
6/?
You end up with protein fractions like this, with the relative quantities of each protein in the subcellular locales. Previously, in the original academic version of this approach, we orthogonally validated some of the fundamental biochemistry of this fractionation: www.cell.com/cell-reports...
5/?
5/?
July 2, 2025 at 3:35 PM
You end up with protein fractions like this, with the relative quantities of each protein in the subcellular locales. Previously, in the original academic version of this approach, we orthogonally validated some of the fundamental biochemistry of this fractionation: www.cell.com/cell-reports...
5/?
5/?